The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its ...

The company's application included a submitted dose of 0.04 millimole gadolinium per kilogram of body weight. If approved, gadoquatrane would become the lowest dose macrocyclic gadolinium-based ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

Bayer meanwhile recently started a fourth phase 3 trial of elinzanetant that will test the drug's ability to treat VMS associated with endocrine therapy of breast cancer. GlobalData recently ...

The first successes of the turnaround are visible,' said Markus Manns, a portfolio manager at Union Investment in Frankfurt.

Bayer AG Innovation Procurement has signed a multi-year extension with Scientist.com, becoming Bayer’s preferred global ...

Berlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients ...

Bayer seeks US FDA approval for contrast agent, gadoquatrane for contrast-enhanced MRI of the CNS and other body regions: Berlin Wednesday, June 18, 2025, 09:00 Hrs [IST] Bayer an ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...